SMAD3 and pulmonary fibrosis: In mice with pulmonary fibrosis, tail-intravenous injection of miR-29a agomir would result in a significant reduction in TGF-β1 and CTGF content, the severity of pulmonary fibrosis, as well as the suppression of Smad3 expression in the nucleus (Yun and Wang, 2024).